对香菊胶囊治疗鼻窦炎的有效性和安全性进行系统评价。检索中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献数据库(CBM)、Cochrane Library、PubMed、EMbase、Web of Science,筛选香菊胶囊治疗鼻窦炎的随机对照试验(RCTs)...对香菊胶囊治疗鼻窦炎的有效性和安全性进行系统评价。检索中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献数据库(CBM)、Cochrane Library、PubMed、EMbase、Web of Science,筛选香菊胶囊治疗鼻窦炎的随机对照试验(RCTs),并用RevMan 5.3软件对最终纳入的研究进行Meta分析。共纳入29项研究,总样本量4331例,试验组2196例,对照组2135例。Meta分析结果显示,常规治疗+香菊胶囊的显效率(RR=1.30,95%CI[1.15,1.47],P<0.00001)、总有效率(RR=1.19,95%CI[1.16,1.23],P<0.00001)和Lund-Mackay评分(MD=-1.23,95%CI[-1.39,-1.07],P<0.00001)优于仅使用常规治疗;常规治疗+桉柠蒎肠溶软胶囊+香菊胶囊对总有效率(RR=1.14,95%CI[1.07,1.21],P<0.0001)和VAS评分的改善优于常规治疗+桉柠蒎肠溶软胶囊(MD_(头痛)=-1.29,95%CI[-1.48,-1.10],P<0.00001;MD_(鼻塞)=-1.08,95%CI[-1.21,-0.95],P<0.00001;MD_(嗅觉障碍)=-1.05,95%CI[-1.23,-0.87],P<0.00001;MD_(面部障碍)=-1.38,95%CI[-1.49,-1.27],P<0.00001);常规治疗+克拉霉素+香菊胶囊治疗鼻窦炎的总有效率(RR=1.15,95%CI[1.08,1.21],P<0.00001)优于常规治疗+克拉霉素,但对显效率(RR=1.27,95%CI[0.98,1.65],P=0.07)的改善无差异;克拉霉素+香菊胶囊对鼻窦炎患者显效率(RR=2.16,95%CI[1.47,3.18],P<0.0001)和总有效率(RR=1.48,95%CI[1.28,1.72],P<0.00001)的提高以及CT评分(MD=-1.87,95%CI[-2.01,-1.74],P<0.00001)的改善明显优于单用克拉霉素。试验序贯分析(TSA)表明,目前主要结局指标的累计样本量已经达到期望值。不良反应主要为嗜睡、腹泻和腹痛等,均与香菊胶囊无直接关系。基于现有数据和方法,香菊胶囊联合多种治疗能够提高鼻窦炎治疗的显效率和总有效率,改善CT评分、VAS评分和Lund-Mackay评分,无严重不良反应。今后仍需采用大样本、设计严谨、符合国际规范的临床试验方案来验证香菊胶囊治疗鼻窦炎的有效性与安全性。展开更多
系统评价虎力散治疗膝骨关节炎的有效性和安全性,以期为临床实践提供参考依据.检索Cochrane Library、EM-base、PubMed、Web of Science、中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献服务系统(SinoMed),搜索国内外数...系统评价虎力散治疗膝骨关节炎的有效性和安全性,以期为临床实践提供参考依据.检索Cochrane Library、EM-base、PubMed、Web of Science、中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献服务系统(SinoMed),搜索国内外数据库中关于虎力散胶囊治疗膝骨关节炎的随机对照试验(RCT),检索时限均为建库至2021年11月15日.由2名研究者独立筛选文献、提取资料,使用风险偏倚评估(ROB)工具对纳入研究的偏倚风险进行评价,采用RevMan 5.4软件进行Meta分析.共纳入12项RCTs,样本量1703例,其中试验组1075例,对照组628例.Meta分析结果显示,①虎力散胶囊+常规治疗对膝骨关节炎的症状缓解率(RR=1.19,95%CI[1.09,1.30],P<0.0001)、Lysholm评分(MD=11.17,95%CI[7.35,15.00],P<0.00001)、视觉模拟量表(VAS)评分(MD=-0.99,95%CI[-1.30,-0.68],P<0.00001)、膝关节功能评分(RR=8.94,95%CI[6.51,11.37],P<0.00001)优于常规治疗,差异有统计学意义.②虎力散胶囊治疗膝骨关节炎的症状缓解率(RR=1.38,95%CI[1.13,1.69],P=0.002)、膝关节功能评分(MD=2.88,95%CI[0.81,4.94],P=0.006)优于常规治疗,差异有统计学意义;对VAS评分的改善差异无统计学意义(MD=-0.57,95%CI[-1.42,0.29],P=0.19).③虎力散胶囊+常规治疗对膝骨关节炎的症状缓解率对比追风透骨胶囊+常规治疗,差异无统计学意义(RR=1.07,95%CI[0.91,1.25],P=0.44).④虎力散胶囊+常规治疗对膝骨关节炎的Lequesne评分对比常规治疗/追风透骨胶囊+常规治疗,差异无统计学意义(MD=-2.17,95%CI[-6.29,1.96],P=0.30);试验组不良反应发生率低于对照组,差异有统计学意义(RR=0.57,95%CI[0.34,0.96],P=0.03).结果表明,使用虎力散胶囊/虎力散胶囊+常规治疗,可提高膝骨关节炎患者的症状缓解率、Lysholm评分、膝关节功能评分和VAS评分,同时缓解膝关节疼痛、肿胀、运动限制等症状,目前尚未发现严重不良反应.今后仍需采用大样本、设计严谨、符合国际规�展开更多
Objective:To systematically evaluate the effectiveness and safety of Zhichuanling Oral Liquid(止喘灵口服液)in the treatment of bronchitis asthma.Methods:A systematic search of CNKI,Wanfang Data,VIP,CBM,Cochrane Librar...Objective:To systematically evaluate the effectiveness and safety of Zhichuanling Oral Liquid(止喘灵口服液)in the treatment of bronchitis asthma.Methods:A systematic search of CNKI,Wanfang Data,VIP,CBM,Cochrane Library,PubMed,Embase and Web of Science was conducted to screen out randomized controlled trials of Zhichuanling Oral Liquid in the treatment of bronchial asthma.Meta-analysis and systematic evaluation of the included studies were conducted to finally included researches using the Cochrane Handbook 5.1 evaluation standard tool and RevMan 5.3 software.Results:Five studies were included,with a total sample size of 354 cases,176 in experimental group and 178 in control group.Meta-analysis showed that the total effective rate of Zhichuanling Oral Liquid combined with conventional treatment was better than that of conventional treatment alone(RR=1.27,95%CI[1.13-1.42],P<0.0001).Conclusion:Based on the existing data and methods,Zhichuanling Oral Liquid combined with conventional Western medicine in the treatment of bronchial asthma can improve the total effective rate.However,the quality of the included studies is not high and the number is small,so it is necessary to adopt clinical trial protocols with large samples,rigorous design and in line with international standards to improve the quality of evidence in the future.展开更多
文摘对香菊胶囊治疗鼻窦炎的有效性和安全性进行系统评价。检索中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献数据库(CBM)、Cochrane Library、PubMed、EMbase、Web of Science,筛选香菊胶囊治疗鼻窦炎的随机对照试验(RCTs),并用RevMan 5.3软件对最终纳入的研究进行Meta分析。共纳入29项研究,总样本量4331例,试验组2196例,对照组2135例。Meta分析结果显示,常规治疗+香菊胶囊的显效率(RR=1.30,95%CI[1.15,1.47],P<0.00001)、总有效率(RR=1.19,95%CI[1.16,1.23],P<0.00001)和Lund-Mackay评分(MD=-1.23,95%CI[-1.39,-1.07],P<0.00001)优于仅使用常规治疗;常规治疗+桉柠蒎肠溶软胶囊+香菊胶囊对总有效率(RR=1.14,95%CI[1.07,1.21],P<0.0001)和VAS评分的改善优于常规治疗+桉柠蒎肠溶软胶囊(MD_(头痛)=-1.29,95%CI[-1.48,-1.10],P<0.00001;MD_(鼻塞)=-1.08,95%CI[-1.21,-0.95],P<0.00001;MD_(嗅觉障碍)=-1.05,95%CI[-1.23,-0.87],P<0.00001;MD_(面部障碍)=-1.38,95%CI[-1.49,-1.27],P<0.00001);常规治疗+克拉霉素+香菊胶囊治疗鼻窦炎的总有效率(RR=1.15,95%CI[1.08,1.21],P<0.00001)优于常规治疗+克拉霉素,但对显效率(RR=1.27,95%CI[0.98,1.65],P=0.07)的改善无差异;克拉霉素+香菊胶囊对鼻窦炎患者显效率(RR=2.16,95%CI[1.47,3.18],P<0.0001)和总有效率(RR=1.48,95%CI[1.28,1.72],P<0.00001)的提高以及CT评分(MD=-1.87,95%CI[-2.01,-1.74],P<0.00001)的改善明显优于单用克拉霉素。试验序贯分析(TSA)表明,目前主要结局指标的累计样本量已经达到期望值。不良反应主要为嗜睡、腹泻和腹痛等,均与香菊胶囊无直接关系。基于现有数据和方法,香菊胶囊联合多种治疗能够提高鼻窦炎治疗的显效率和总有效率,改善CT评分、VAS评分和Lund-Mackay评分,无严重不良反应。今后仍需采用大样本、设计严谨、符合国际规范的临床试验方案来验证香菊胶囊治疗鼻窦炎的有效性与安全性。
文摘系统评价虎力散治疗膝骨关节炎的有效性和安全性,以期为临床实践提供参考依据.检索Cochrane Library、EM-base、PubMed、Web of Science、中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献服务系统(SinoMed),搜索国内外数据库中关于虎力散胶囊治疗膝骨关节炎的随机对照试验(RCT),检索时限均为建库至2021年11月15日.由2名研究者独立筛选文献、提取资料,使用风险偏倚评估(ROB)工具对纳入研究的偏倚风险进行评价,采用RevMan 5.4软件进行Meta分析.共纳入12项RCTs,样本量1703例,其中试验组1075例,对照组628例.Meta分析结果显示,①虎力散胶囊+常规治疗对膝骨关节炎的症状缓解率(RR=1.19,95%CI[1.09,1.30],P<0.0001)、Lysholm评分(MD=11.17,95%CI[7.35,15.00],P<0.00001)、视觉模拟量表(VAS)评分(MD=-0.99,95%CI[-1.30,-0.68],P<0.00001)、膝关节功能评分(RR=8.94,95%CI[6.51,11.37],P<0.00001)优于常规治疗,差异有统计学意义.②虎力散胶囊治疗膝骨关节炎的症状缓解率(RR=1.38,95%CI[1.13,1.69],P=0.002)、膝关节功能评分(MD=2.88,95%CI[0.81,4.94],P=0.006)优于常规治疗,差异有统计学意义;对VAS评分的改善差异无统计学意义(MD=-0.57,95%CI[-1.42,0.29],P=0.19).③虎力散胶囊+常规治疗对膝骨关节炎的症状缓解率对比追风透骨胶囊+常规治疗,差异无统计学意义(RR=1.07,95%CI[0.91,1.25],P=0.44).④虎力散胶囊+常规治疗对膝骨关节炎的Lequesne评分对比常规治疗/追风透骨胶囊+常规治疗,差异无统计学意义(MD=-2.17,95%CI[-6.29,1.96],P=0.30);试验组不良反应发生率低于对照组,差异有统计学意义(RR=0.57,95%CI[0.34,0.96],P=0.03).结果表明,使用虎力散胶囊/虎力散胶囊+常规治疗,可提高膝骨关节炎患者的症状缓解率、Lysholm评分、膝关节功能评分和VAS评分,同时缓解膝关节疼痛、肿胀、运动限制等症状,目前尚未发现严重不良反应.今后仍需采用大样本、设计严谨、符合国际规�
基金The 2018 National Key R&D Program of the Ministry of Science and Technology"Research on the Modernization of Traditional Chinese Medicine"project"Evidence-based evaluation and demonstration study on the mechanism of effects of the treatment of major diseases after the marketing of ten large varieties of proprietary Chinese medicines and classic formulas"(2018YFC1707400)。
文摘Objective:To systematically evaluate the effectiveness and safety of Zhichuanling Oral Liquid(止喘灵口服液)in the treatment of bronchitis asthma.Methods:A systematic search of CNKI,Wanfang Data,VIP,CBM,Cochrane Library,PubMed,Embase and Web of Science was conducted to screen out randomized controlled trials of Zhichuanling Oral Liquid in the treatment of bronchial asthma.Meta-analysis and systematic evaluation of the included studies were conducted to finally included researches using the Cochrane Handbook 5.1 evaluation standard tool and RevMan 5.3 software.Results:Five studies were included,with a total sample size of 354 cases,176 in experimental group and 178 in control group.Meta-analysis showed that the total effective rate of Zhichuanling Oral Liquid combined with conventional treatment was better than that of conventional treatment alone(RR=1.27,95%CI[1.13-1.42],P<0.0001).Conclusion:Based on the existing data and methods,Zhichuanling Oral Liquid combined with conventional Western medicine in the treatment of bronchial asthma can improve the total effective rate.However,the quality of the included studies is not high and the number is small,so it is necessary to adopt clinical trial protocols with large samples,rigorous design and in line with international standards to improve the quality of evidence in the future.
